AstraZeneca’s $2B Summit investment creates major oncology catalyst

AstraZeneca took a $2 billion equity stake in Summit Therapeutics, acquiring approximately 12% ownership and planning combination trials involving ivonescimab and AstraZeneca’s CLDN18.2 ADC. Ivonescimab’s November 14, 2026 FDA action date is the next major catalyst, with clinical execution and combination efficacy determining whether the deal supports a broader GI-cancer opportunity.